6. Hepatic Encephalopathy

Quick Recap

GI & Hepatology System, Protocol 6/13. Nests with Acute-on-Chronic Liver Failure and Acute Liver Failure protocols — note the encephalopathy management principles DIFFER meaningfully between cirrhosis-associated HE (this protocol) and ALF-associated encephalopathy/cerebral edema (see ALF protocol).

1. Definition & Presentation

Hepatic encephalopathy (HE) = neuropsychiatric dysfunction resulting from liver disease/portosystemic shunting. Early symptoms are often SUBTLE — mood changes, insomnia — progressing to agitation and coma. Graded via West Haven criteria (see Acute Liver Failure protocol Section 4 for the full grading table): Grade 1 (trivial lack of awareness) through Grade 4 (coma).

The mediators of HE are not fully understood. Serum ammonia is a biomarker but may NOT correlate well with clinical severity — do not rely on an ammonia level alone to grade severity or guide treatment intensity; treat the clinical picture, not the number.

2. Precipitant Identification — The Essential First Step

Any new or worsening HE, regardless of severity, should prompt an active search for a precipitant — HE is very often a SECONDARY phenomenon signaling another acute problem, not a primary progression of liver disease alone.

Common precipitants: infection (including spontaneous bacterial peritonitis — always have a low threshold to tap ascites in new/worsening HE), GI hemorrhage (blood is a protein/nitrogen load and a potent HE trigger), exposure to neuroactive medications (benzodiazepines, opioids) — review the medication list specifically for these agents in any patient with new/worsening HE, as they are a common iatrogenic driver. Other precipitants to consider broadly: electrolyte disturbance (hypokalemia, alkalosis), dehydration/over-diuresis, constipation, renal failure, TIPS placement (see Upper GI Bleed protocol — TIPS is a recognized cause of new/worsened HE given the portosystemic shunt it creates).

3. Immediate Stabilization (ABCDE)

Airway: Grade 3-4 HE carries aspiration risk — assess airway protection capability; low threshold for intubation with advanced-grade HE, particularly if endoscopy or other procedures are planned.

Circulation/Disability: treat the identified precipitant aggressively in parallel with HE-directed therapy — lactulose alone will not resolve HE if an untreated infection or ongoing GI bleed is driving it.

Checklist:

4. Pharmacologic Treatment

Titrate lactulose to 2-3 soft stools per day — this is the actual clinical endpoint, not a specific volume/dose; both under- and over-dosing (leading to dehydration, hypernatremia, or worsening HE from volume depletion) are pitfalls.

5. Contrast: HE Management in ALF Is Different

Important cross-reference: in Acute Liver Failure specifically (no underlying cirrhosis), no benefit of gut decontamination or lactulose has been demonstrated despite ammonia elevation being associated with herniation risk in that population — the standard cirrhosis-HE pharmacologic approach (lactulose, rifaximin, LOLA) does NOT have the same evidence base in ALF. Do not assume the cirrhotic-HE treatment paradigm transfers directly to ALF-associated encephalopathy/cerebral edema — see the Acute Liver Failure protocol for that population's distinct approach (ICP monitoring, osmotherapy, hyperventilation as a temporizing measure).

6. Sedation Considerations

If sedation is required (e.g., for a procedure or agitation), avoid benzodiazepines where possible given their direct neuroactive-precipitant role in HE (Section 2). Fentanyl or morphine can be used, but avoid morphine specifically in concomitant renal dysfunction (active metabolite accumulation risk). Minimize sedative exposure generally, given the added burden on an already encephalopathic patient's mental status assessment and aspiration risk.

7. Investigations

Ammonia level (biomarker, but interpret cautiously given poor severity correlation — Section 1); diagnostic paracentesis with cell count/culture if ascites present; infectious workup (blood/urine cultures, CXR) per precipitant search; electrolytes (especially potassium, given hypokalemia's role in promoting renal ammoniagenesis and worsening HE); renal function (affects LOLA eligibility and overall management); medication reconciliation for neuroactive drug exposure; consider head imaging if diagnostic uncertainty exists or focal findings are present (to exclude a structural/other cause of altered mental status rather than assuming HE by default).

8. Organ Support

Airway protection for Grade 3-4 HE; standard supportive ICU care while precipitant treatment and lactulose/rifaximin take effect; nutrition support without protein restriction (per the Acute-on-Chronic Liver Failure and Acute Liver Failure protocols' shared principle — protein restriction is outdated practice and does not improve HE outcomes while worsening nutritional status).

9. Consultation Matrix

10. Monitoring Framework

Serial mental status/West Haven grading, stool frequency (lactulose titration endpoint), electrolytes (especially potassium, sodium), renal function, ammonia trend (as a rough adjunct, not primary severity marker), airway protection reassessment as grade fluctuates.

11. Complications

Aspiration (advanced-grade HE with impaired airway protection), lactulose-induced dehydration/electrolyte disturbance from over-titration, missed precipitant leading to unresolving HE despite lactulose/rifaximin, medication-induced HE worsening if neuroactive drugs are not identified/discontinued. Prevention: precipitant-focused workup as the primary strategy (not just escalating HE-directed pharmacotherapy blindly), careful lactulose titration to the 2-3 stool/day endpoint, medication reconciliation. Rescue: airway protection/intubation for advanced-grade HE, aggressive precipitant-specific treatment (antibiotics for infection, endoscopy for GI bleed, etc.).

12. Escalation & De-escalation

Escalate: progressing HE grade despite lactulose -> reassess for an unaddressed precipitant (do not simply increase lactulose dose without re-searching for cause), add rifaximin if not already started, consider airway protection at Grade 3-4.

De-escalate: improving mental status, precipitant resolved/treated, stool frequency at target -> continue maintenance lactulose (often long-term for secondary prevention), taper any sedation used, resume standard diet with adequate (not restricted) protein.

13. ICU Discharge Criteria

Mental status returned to baseline or a stable, safe grade, precipitant identified and treated, lactulose titrated to effect with a clear maintenance plan, airway protection concerns resolved, outpatient hepatology follow-up arranged for recurrent HE prevention planning.

14. Documentation & Medicolegal Checklist

15. Key Guidelines

Vilstrup H, Amodio P, Bajaj J, et al. Hepatic encephalopathy in chronic liver disease: 2014 practice guideline by AASLD and EASL. Hepatology. 2014;60(2):715-735 — primary reference for cirrhosis-associated HE management.

16. Controversies

The true severity-correlation value of serum ammonia remains debated — it is retained as a biomarker/adjunct despite acknowledged poor correlation with clinical grade, and some clinicians over-rely on trending it as a primary management guide despite this known limitation. LOLA's role remains an accepted-but-modestly-evidenced adjunct rather than a first-line, strongly evidence-based therapy. The management paradigm split between cirrhotic HE (lactulose/rifaximin-responsive) and ALF-associated encephalopathy (lactulose/gut decontamination NOT shown beneficial) is an important, sometimes under-recognized distinction that can lead to inappropriate extrapolation of cirrhotic-HE practices to the ALF population.

17. References

1. Al-Obaid L, Korenblat KM. End-Stage Liver Disease (Hepatic Encephalopathy section). Washington Manual of Critical Care, 4th ed, 2025 (Ch. 51).
2. Kumar A, Sultan S. Acute Liver Failure (contrasting encephalopathy management). Washington Manual of Critical Care, 4th ed, 2025 (Ch. 49).
3. Vilstrup H, Amodio P, Bajaj J, et al. Hepatic encephalopathy in chronic liver disease: 2014 practice guideline by AASLD and EASL. Hepatology. 2014;60(2):715-735.
4. Drug dosing reference tables (Lactulose, Neomycin, Rifaximin). Washington Manual of Critical Care, 4th ed, 2025 (Ch. 95, drug appendix).

See also: Acute-on-Chronic Liver Failure and Acute Liver Failure (GI & Hepatology System) for the broader hepatic decompensation context and the important contrast in encephalopathy management approach between cirrhotic HE and ALF.